anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:An anticoagulant substance derived from human placanta. Molecular weight; 24000+ or -2000 (SDS-polyacrylamide gel electrophoresis). Isoelectric point; 4.7+ or -0.1 (isoelectric column focusing with Ampholyte). Stability; Inactivated by heat treatment at 50 deg.C for 30min, stable at 4-10pH and stable at 37 deg.C in blood plasma for 30min. Action; Prolonging recalcifying coagulation time, prothrombin time and activated paratial thromboplastin time. Amino acid analysis; Shown in the table. USE:An anticoagulant substance. PREPARATION:A human placenta is homogenized and the resultant hoogenate is centrifuged to give a centrifugal residue or centrifugal supernatant, which is fractionated to afford a microsomic fraction. The resultant microsomic fraction is then extracted with a surfactant and/or chelating agent to give an extract, which is separated and purified to provide the aimed anticoagulant substance. The dose thereof is 10mug-10mg/kg/day and the dosage form is injection.
The only important innovation is to use the S protein ligand-complementary binding-Ab 2 beta antibody-complementary binding-Ab 1 antibody-complementary binding-ACE 2 antigen receptor in the technical route. Specific Ab2 beta antibodies and Fab antibody drugs thereof which specifically bind to the S protein ligand are prepared. Since the anti-idiotype Ab2 beta antibody is an "intra-antigen image" like a nail and a nail in a mirror, its configuration is similar to an ACE2 epitope. The Ab2 beta antibody thus mimics the target cell surface ACE2 antigen receptor and is capable of binding to any variant new coronavirus or variant strain of new coronavirus. Specifically blocks any mutated novel coronavirus from entering cell replication, causing damage to the respiratory tract and including the eye. The invention patent is searched at present, and no invention or family patent exists at home and abroad.
Postoperative visual loss resulting from a surgical procedure not performed on the eye is a devastating outcome for the patient and poorly understood by the medical community. It is potentially a preventable complication. Diminished blood supply to the optic nerve, affecting both the anterior or posterior portions of the optic nerve, is the most common cause of postoperative visual loss. Other, less common causes include occlusion of the retinal artery and vein, a retinal embolism and cortical blindness. The incidence of postoperative visual loss increases in patients undergoing cardiopulmonary bypass and prone spine surgery. Although the etiology of post-operative visual loss is unknown, it is thought to be multifactorial, and several potential risk factors have been identified, including degree of low blood pressure, preoperative hematocrit, external compression of the eye, amount of blood loss, prolonged duration of surgical time and increased pressure in the eye associated with positioning. To date studies have focused on the mechanism associated with the visual loss. We would like to focus on the feasibility of using a monitor which may signal loss of visual function intraoperatively.
Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue Levorphanol Tartrate Tablets in a patient physically dependent on opioids. Rapid tapering of Levorphanol Tartrate Tablets in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing Levorphanol Tartrate Tablets, gradually taper the dosage using a patient-specific plan that considers the following: the dose of Levorphanol Tartrate Tablets the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper (see DOSAGE AND ADMINISTRATION, and WARNINGS).

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs (see Pregnancy).
Internuclear ophthalmoparesis (INO) is a horizontal eye movement disorder that is associated with a lesion at the medial longitudinal fasciculus (MLF). One-and-a-half syndrome occurs when the lesion involves the MLF and the ipsilateral abducens nuclei or the paramedian pontine reticular formation (PPRF) in the dorsomedial tegmentum of the pons. When the lesion is large enough, the fascicles of the facial nerve (CNVII) can also be involved, resulting in an ipsilateral facial nerve palsy. In combination with one-and-a-half syndrome, this condition becomes eightand- a- half syndrome (EHS). Here, we describe a unique case of EHS in a 72-year-old male with multiple ischemic stroke risk factors who presented with INO, conjugate gaze palsy, ipsilateral facial palsy, and a transient contralateral hemiparesis. Recognizing this pattern of neurologic deficits improves localization of the lesion, prevents misdiagnosis of Bell's Palsy, and expedites proper treatment.
The disclosure provides therapies that are useful in the prevention of pulmonary vascular remodeling and treatment of vascular conditions. In particular, the disclosure provides methods of treatment of pulmonary vascular diseases comprising administration of an inhibitor of programmed cell death protein 1 (PD-1) or the corresponding programmed death-ligand 1 (PD-L1). These methods comprise administering to a subject a PD-1 or PD-L1 inhibitor such as a monoclonal antibody. Further provided herein are diagnostic methods for assessing patient sensitivity to therapies. Methods of identifying a subject having a pulmonary hypertension that is sensitive to treatment with a PD-L1 inhibitor or a PD-1 inhibitor are provided. Subjects identified as having a pulmonary hypertension that is sensitive to anti-PD-L1 treatment may be subsequently administered a PD-L1 inhibition treatment.
Cardiovascular disease is one of the leading causes of death worldwide. Evidence suggests that alterations in the gut microbiome could play a role in cardiovascular diseases, including heart failure. The purpose of this study was to evaluate the effect of synbiotics on serum paraoxonase 1(PON1), soluble CD163/soluble TNF-like weak inducer of apoptosis (sCD163/sTWEAK), and lipid profile, which are involved in heart failure in patients with chronic heart failure. In this triple-blind randomized clinical trial, 90 eligible patients were included in the study. They were randomly assigned to receive one capsule (500 mg) of synbiotics or a placebo daily for ten weeks. Serum PON1, sCD163/sTWEAK, and lipid profiles were measured at the beginning and end of the study. The data were analyzed by SPSS 24, and the p-value < 0.05 was considered statistically significant. Among 90 patients who met the inclusion criteria, 80 completed the study. The primary outcomes showed a small effect on sTWEAK, with an adjusted standard mean difference (SMD) of 0.2. However, no significant changes were observed in sCD163/sTWEAK (SMD: 0.16). Secondary outcomes indicated no changes in PON1, total cholesterol (TC), or LDL-C levels. However, there was an increase in HDL-C levels (adjusted SMD: 0.46, 95% CI: 0.02-0.91) and a decrease in TG and TC/HDL levels (adjusted SMD: - 0.5 and - 0.3, respectively) in the synbiotic group. A favorable effect of synbiotics on sTWEAK, HDL, TG, and TC/HDL of patients with heart failure was observed, but no statistically significant effect was found on sCD163/sTWEAK, PON1, LDL, and TC factors.
ETHNOPHARMACOLOGICAL RELEVANCE: As the second-largest traditional medical system in China, Tibetan medicine has a long history and abundant resources. To promote the development of the Tibetan medicine industry, it is essential to study the pharmacological activities of Tibetan medicine based on its traditional usage methods.
AIM OF THE STUDY: Pneumonia has been a worldwide health problem with high morbidity and mortality rates, especially in the context of the COVID-19 epidemic. Given the unique advantages of traditional Tibetan medicine in treating pulmonary diseases, further research is warranted to develop potential anti-pneumonia drugs.
MATERIALS AND METHODS: In our study, the potential combined decoction from traditional Tibetan medicine was determined by the data mining method. The antioxidant activity in vitro, anti-inflammatory effects on the macrophage cell model, as well as the anti-pulmonary inflammation effects on the LPS-induced mice model, have been explored to investigate the potential anti-pneumonia role of the decoction. Additionally, we conducted network pharmacology analysis to identify the potential targets against pneumonia, which were further confirmed by western blot assays.
RESULTS: Following the combination therapy of Pterocephalodes hookeri (C.B.Clarke) V.Mayer & Ehrend. and Onosma hookeri var. longiflora (Duthie) A.V.Duthie ex Stapf ('P-O'), the clearance of DPPH radical and the total reducing power were all improved, as well as alleviated the toxicity. On the in vitro level, 'P-O' pre-treatment reduced the secretion of NO, TNF-α, IL-6, and IL-1β in LPS-stimulated RAW264.7 cells, while promoting the concentration of IL-10. Meanwhile, on the in vivo level, the 'P-O' pre-treating also could alleviate LPS-induced pulmonary inflammation by reducing the pulmonary edema and leakage of the lung microvascular, improving the pathological change of lung tissue and regulating the cytokines content in bronchoalveolar lavage fluid (BALF). Furthermore, network pharmacology analysis revealed that the mechanism of 'P-O' in treating pneumonia in a multi-component, multi-target, and multi-pathway network, with the TLR4/NF-κB signaling pathway playing a crucial role, as demonstrated by the western blot assay results.
CONCLUSION: In summary, the combination therapy of 'P-O' exhibited good antioxidant activity and anti-inflammatory activity in vitro, as well as a therapeutic effect against pulmonary inflammation in vivo. These findings provide evidence for the clinical application of 'P-O' and offer new approaches for treating pneumonia.
The present invention relates to the discovery of a novel isoform of phosphatidylinositide binding protein, referred to herein a “general receptors for phosphoinositides” or “GRPs”. The GRP molecules show a modular structure comprising a domain homologous to the yeast SEC7 gene product and a pleckstrin homology (PH) domain. GRP proteins exhibit specific high affinity binding to products of the lipid kinase phosphatidylinositol-3-OH kinase, such as phosphotidylinositol-3,4,5. As described herein, GRP proteins may function as adaptors between membrane signalling and multiple downstream targets. Thus, GRP polypeptides potentially mediate multiple signalling events such as cell adhesion and membrane trafficking, among others. This invention describes isolated and antisense nucleic acids molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which GRP gene has been introduced or disrupted. In addition, the invention provides isolated GRP proteins, fusion proteins, antigenic peptides and anti-GRP antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The invention further provides a method of cloning novel phosphatidylinositol binding protein.
The invention discloses a traditional Chinese medicine for treating postherpetic neuralgia. The traditional Chinese medicine comprises the following components in percentage by weight: 20-30% of radix bupleuri, 15-20% of scutellaria baicalensis, 15-20% of ginger, 15-20% of pinellia ternate, 10-15% of ginseng and 10-15% of honey-fried licorice root as well as 4 Chinese dates. The preparation and application method comprises the following steps: weighing the traditional Chinese medicines, boiling in water, and taking before half an hour of breakfast and supper for 10 days as one treatment course. The traditional Chinese medicine mainly aims at harmonizing yang shortage and clearing liver and gall. Twenty cases of thirty patients are treated, excellent curative effect is achieved on six cases, the effect is taken on 3 cases, and the medicine is ineffective on one case, and the total effective rate is 96.7%. The medicine is free of toxic and side effects, free of drug dependence, simple in formula, convenient to take, low in cost, good in curative effect and high in effective rate.
Risk Summary

If sofosbuvir and velpatasvir is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin prescribing information for more information on ribavirin-associated risks of use during pregnancy.

No adequate human data are available to establish whether or not sofosbuvir and velpatasvir pose a risk to pregnancy outcomes. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with sofosbuvir or velpatasvir at exposures greater than those in humans at the recommended human dose (RHD) [see Data]. During organogenesis in the mouse, rat, and rabbit, systemic exposures (AUC) to velpatasvir were approximately 31 (mice), 6 (rats), and 0.4 (rabbits) times the exposure in humans at the RHD, while exposures to the predominant circulating metabolite of sofosbuvir (GS-331007) were approximately 4 (rats) and 10 (rabbits) times the exposure in humans at the RHD. In rat pre/postnatal development studies, maternal systemic exposures (AUC) to velpatasvir and GS-331007 were approximately 5 times the exposures of each component in humans at the RHD.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Data

Sofosbuvir: Sofosbuvir was administered orally to pregnant rats (up to 500 mg/kg/day) and rabbits (up to 300 mg/kg/day) on gestation days 6 to 18 and 6 to 19, respectively, and also to rats (oral doses up to 500 mg/kg/day) on gestation day 6 to lactation/post-partum day 20. No significant effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at the highest doses tested. The systemic exposures (AUC) of the predominant circulating metabolite of sofosbuvir (GS-331007) during gestation were approximately 4 (rats) and 10 (rabbits) times the exposure in humans at the RHD.

Velpatasvir: Velpatasvir was administered orally to pregnant mice (up to 1000 mg/kg/day), rats (up to 200 mg/kg/day), and rabbits (up to 300 mg/kg/day) on gestation days 6 to 15, 6 to 17, and 7 to 20, respectively, and also to rats (oral doses up to 200 mg/kg) on gestation day 6 to lactation/post-partum day 20. No significant effects on embryo-fetal (mice, rats, and rabbits) or pre/postnatal (rats) development were observed at the highest doses tested. The systemic exposures (AUC) of velpatasvir during gestation were approximately 31 (mice), 6 (rats), and 0.4 (rabbits) times the exposure in humans at the RHD.
Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biological membrane, wherein a biological membrane is contacted with a conjugate containing a biologically active agent that is covalently attached to a transport polymer. In one embodiment, the polymer consists of from 6 to 25 subunits, at 50 % of which contain a guanidino or amidino sidechain moiety. The polymer is effective to impart to the attached agent a rate of trans-membrane transport across a biological membrane that is greater than the rate of trans-membrane transport of the agent in non-conjugated form. The transport-enhancing polymers are exemplified, in a preferred embodiment, by peptides in which arginine residues constitute the subunits. Such a polyarginine peptide may be composed of either all D-, all L- or mixed D- and L-arginines, any may include additional amino acids. More preferably, at least one, and preferably all of the subunits are D-arginine residues, to enhance biological stability of the polymer during transit of the conjugate of its biological target.
Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
Gene therapy of SCO is based on the transplantation of genetically modified HSCs. Several LV approaches based on gene addition consist in transducing patient HSCs with a lentiviral vector expressing an anti-sickling β-like globin chain such as use of β AS3  HBB anti-sickling variants. Here, the inventors have improved the design of the LV-AS3 vector to treat SCO patients. These LVs allow the simultaneous expression of the potent anti-sickling β AS3 -globin and an artificial miR (amiR) silencing the β S -globin. The reduction of β S -globin levels will increase the incorporation of β AS3 -globin in Hb tetramers, which should increase the proportion of corrected RBCs in SCO patients. The inventors selected the best-performing miRs, and modified the therapeutic β AS3 -globin transgene by inserting silent mutations to avoid the recognition by the amiR and the silencing of the transgene.
You will be expected to keep diet records for 17 consecutive days. You will start with a fasting screening visit (only water allowed). A physical exam and Medical history it taken at screening visit. Your body composition will be gathered by CT and Dexa Scan. Blood and urine will be collected for a chemical profile and other determinations. Questionnaires will be administered along with an accelerometer to be worn for the remainder of the study. The final day you will return the dietary records, accelerometer, and a few procedures will be performed as weight.
The invention discloses a medicine composition as well as a preparation method, a preparation and an application thereof. The medicine composition comprises the following components in parts by weight: 20-40 parts of sand-fried arisaema with bile, 50-70 parts of wine-fried baikal skullcap root, 20-40 parts of fried ephedra herb, 20-40 parts of fried common coltsfoot flower, 50-70 parts of dried tangerine peel, 50-70 parts of Indian buead and 20-40 parts of liquorice root. The preparation method comprises the following steps: weighing the components according to a prescription proportion of the medicine composition, and performing crushing, screening and uniform mixing or performing extraction and concentration to obtain a target object. A preparation method of the preparation comprises the following step: adding pharmaceutically acceptable auxiliary materials into the medicine composition to prepare powder, tablets, capsules, granules and pills. The application of the medicine composition refers to an application of the medicine composition in preparing medicines for relieving lung injuries caused by PM2.5. The medicine composition disclosed by the invention has certain health protection and treatment effects on the lung injuries caused by PM2.5, and can be used for reducing the injury effects on the lung caused by PM2.5 to a certain extent.
<P>PROBLEM TO BE SOLVED: To provide composite powder exhibiting optical characteristics possessed by a fluorine polymer while maintaining characteristics of powder such as an ultralow content of aggregates and a good particle feeling and to provide a method for producing the powder.  <P>SOLUTION: The composite powder comprises composite particles in which the fluorine polymer is present on the surfaces of particles constituting the powder. The composite powder has 0.01-500 μm average particle diameter. The content of the composite particles having a particle diameter of ≥10 times that of the particles in the powder is ≤10%. The method for producing the composite powder comprises bringing the powder into contact with the fluorine polymer in the presence of a supercritical fluid in a container, then making the resultant mixture of the powder with the fluorine polymer and the supercritical fluid present under a pressure below the critical pressure of the supercritical fluid and thereby compositing the powder with the fluorine polymer.  <P>COPYRIGHT: (C)2004,JPO
Haloperidol + Promethazine + Chlorpromazine are all psychiatric drugs that have been well tested. The combination of these 3 drugs, however, have never been randomised.
A method for adjusting the pressure of one or more cushions in a human transport system is disclosed. The one or more cushions include a plurality of inflatable chambers and a plurality of pressure sensors associated with the cushions. The pressure sensors may be surface pressure sensors or chamber pressure sensors. A processor associated with the human transport system obtains pressure measurements from the plurality of pressure sensors. Based on the pressure measurements, the processor identifies one or more of the plurality of inflatable chambers whose pressure requirements adjustment. The processor then sends commands that cause the human transport system to adjust the pressure in the one or more inflatable chambers. Systems including cushions and processors are also disclosed.